FDA Oncology Announcements

CYP17 inhibitor × Genitourinary × Clear all

3 Announcements

FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer

Drug: Zytiga (abiraterone acetate) · CYP17 inhibitor
Condition: Genitourinary

Expanded Approval forAbiraterone Acetate

Drug: Zytiga Tablets (abiraterone acetate) · CYP17 inhibitor
Condition: Genitourinary

Abiraterone Acetate

Drug: Zytiga Tablets (abiraterone acetate) · CYP17 inhibitor
Condition: Genitourinary